Lakefront Biotherapeutics NV beat EPS estimates 60% of the time across 15 reported quarters (9 beats, 6 misses), averaging +5.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q1 FY26 | not reported | $0.25 | not reported | not reported | |
| Q1 FY25 | not reported | $-2.47 | not reported | not reported | |
| Q1 FY24 | not reported | $0.39 | not reported | not reported | |
| Q3 FY23 | not reported | $0.42 | not reported | not reported | |
| Q2 FY23 | not reported | $0.09 | not reported | not reported | |
| Q1 FY23 | not reported | $0.43 | not reported | not reported | |
| Q4 FY22 | $-1.90 | $-1.99 | -4.7% | Miss | |
| Q3 FY22 | not reported | $0.33 | not reported | not reported | |
| Q2 FY22 | not reported | $-0.31 | not reported | not reported | |
| Q1 FY22 | not reported | $-0.22 | not reported | not reported | |
| Q3 FY21 | $-1.67 | $-1.17 | +29.9% | Beat | |
| Q2 FY21 | $-1.42 | $-1.18 | +16.9% | Beat |
Back to LKFT overview · LKFT holders · LKFT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.